Skip to main content

Scleroderma, Diffuse

3
Pipeline Programs
6
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
2100%
+ 4 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Paracrine
ParacrineCA - San Diego
1 program
1
ADRCsPhase 31 trial
Active Trials
NCT05148598Unknown174Est. Dec 2025
Cumberland Pharmaceuticals
1 program
1
Oral IfetrobanPhase 21 trial
Active Trials
NCT02682511Active Not Recruiting34Est. Aug 2026
Sandoz
SandozAustria - Kundl
1 program
1
rapcabtagene autoleucelPhase 2Cell Therapy1 trial
Active Trials
NCT06655896Recruiting96Est. Aug 2032
Bristol Myers Squibb
1 program
AVID200PHASE_11 trial
Active Trials
NCT03831438Completed9Est. Jun 2020
Inventiva
InventivaDAIX, France
1 program
IVA337PHASE_21 trial
Active Trials
NCT02503644Completed145Est. Oct 2018
Novartis
NovartisBASEL, Switzerland
1 program
rapcabtagene autoleucelPHASE_2Cell Therapy

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ParacrineADRCs
Sandozrapcabtagene autoleucel
Cumberland PharmaceuticalsOral Ifetroban
InventivaIVA337
Bristol Myers SquibbAVID200

Clinical Trials (5)

Total enrollment: 458 patients across 5 trials

NCT05148598ParacrineADRCs

ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma

Start: Feb 2023Est. completion: Dec 2025174 patients
Phase 3Unknown
NCT06655896Sandozrapcabtagene autoleucel

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Start: Oct 2024Est. completion: Aug 203296 patients
Phase 2Recruiting
NCT02682511Cumberland PharmaceuticalsOral Ifetroban

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Start: Jan 2017Est. completion: Aug 202634 patients
Phase 2Active Not Recruiting
NCT02503644InventivaIVA337

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

Start: Oct 2015Est. completion: Oct 2018145 patients
Phase 2Completed
NCT03831438Bristol Myers SquibbAVID200

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

Start: Jan 2019Est. completion: Jun 20209 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 458 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.